Clinical trials: Breast Density
Breast Cancer, Mammographic Density
The Malaysian Soy and Mammographic Density Study
Globally, breast cancer is the most common cancer and the main cause of deaths due to cancer. This is attributed to changes in reproductive habits as well as an increasingly sedentary lifestyle, with low physical activity and…
- Trial name
- MiSo (NCT03686098)
- Testing
- Dietary soy, Soy Supplement
- Where
- Malaysia
- Volunteers
- 282 people, healthy volunteers welcome
- Sponsor
- Cancer Research Malaysia
Breast Cancer, Osteoporosis
Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer
Bone Mineral Density (BMD) as measured by X-ray shows the amount of calcium in the bone. Low BMD may reflect osteoporosis, a condition where there is an increased risk of fracture.
- Trial name
- NCT00587925
- Testing
- Bone Mineral Density
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Bone Geometry and Muscle Density Changes in Postmenopausal Women and Breast Cancer Patients Prescribed Anastrozole
The primary objective of this study is to determine if trabecular or cortical volumetric bone mineral density (vBMD) change over time in postmenopausal breast cancer patients who are prescribed Anastrozole, as measured by pQCT at…
- Trial name
- NCT00421447
- Testing
- Anastrozole
- Where
- Canada
- Volunteers
- 58 people
- Sponsor
- Hamilton Health Sciences Corporation
Breast Cancer
Tailored Screening for Breast Cancer in Premenopausal Women
The Tailored Breast Screening Trial (TBST) is a population-based, non-inferiority randomised trial aimed at evaluating the impact of tailored screening strategies addressed to premenopausal women, by using breast density as…
- Trial name
- TBST (NCT02619123)
- Testing
- Tailored screening according to breast density, Annual invitation to mammography
- Where
- 5 sites in Italy
- Volunteers
- 33,200 people, healthy volunteers welcome
- Sponsor
- Cancer Prevention and Research Institute, Italy
Breast Diseases, Artificial Intelligence
Diagnosis Predictive Modle for Dense Density Breast Tissue Based on Radiomics
It is a prospective, observational cohort study of patients with dense breast tissue. The study was based on the radiomics and other clinicopathological information of patients to establish the diagnostic system for breast…
- Conditions
- Breast Diseases, Artificial Intelligence, Dense Breast Density, Predictive Cancer Model
- Trial name
- NCT04535466
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer
RATIONALE: Studying changes in breast density and blood hormone levels in women receiving anastrozole or exemestane for breast cancer may help doctors learn more about the long-term effects of treatment and may help the study of…
- Trial name
- NCT00516698
- Testing
- polymorphism analysis, high performance liquid chromatography, laboratory biomarker analysis
- Where
- 180 sites in United States
- Volunteers
- 140 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Menopause, Postmenopausal Bone Loss
Effects of Tibilone on Bone Density, Menopause Symptoms and Breast Density in Women After Prophylactic Oophorectomy
Women undergoing surgical menopause often experience marked menopausal side effects but are reluctant to use estrogen or other female hormones to ease the transition to menopause because of worries that the hormones may increase…
- Conditions
- Menopause, Postmenopausal Bone Loss, Breast Cancer
- Trial name
- NCT00165204
- Testing
- Tibolone
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
Anastrozole and Letrozole
Aromatase Inhibitors (AI) are effective for secondary prevention of breast cancer and may soon replace tamoxifen as first-line therapy in the treatment of hormone-sensitive breast cancer.
- Trial name
- NCT00762294
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- UConn Health
Breast Cancer
Assessment of Periodic Screening of Women With Denser Breast Using WBUS and DBT
The purpose of this study is to evaluate the role of technologist-performed whole breast ultrasound for detecting breast cancer in the screening population of women with dense breasts.
- Trial name
- DBTUST (NCT02643966)
- Testing
- Whole breast ultrasound
- Where
- 2 sites in United States
- Volunteers
- 6,266 people, healthy volunteers welcome
- Sponsor
- Wendie Berg
Breast Reconstruction After Mastectomy, Neurotization
Longitudinal Evaluation of Direct Neurotization Technique in Breast Reconstruction With Fully Autologous Components
This clinical trial aims to evaluate whether direct neurotization using fully autologous components during autologous breast reconstruction improves postoperative breast sensation and sensory-related quality of life in women…
- Conditions
- Breast Reconstruction After Mastectomy, Neurotization, Mastectomy and Breast Reconstruction, Peripheral Nerve Regeneration
- Trial name
- NCT07308275
- Testing
- Autologous Breast Reconstruction With Direct Neurotization, Autologous Breast Reconstruction without Neurotization
- Where
- Indonesia
- Volunteers
- 28 people
- Sponsor
- Fakultas Kedokteran Universitas Indonesia
Breast Neoplasms
Breast Mammogram and Tissue Study
Background: Women whose mammograms show a lot of dense areas are more likely to develop breast cancer and to have cancers that are missed by mammograms.
- Trial name
- NCT00475761
- Where
- United States
- Volunteers
- 466 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Low Bone Mineral Density
AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer
The purpose of this trial is to evaluate AMG 162 in the treatment of bone loss in subjects undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer.
- Conditions
- Breast Cancer, Low Bone Mineral Density, Osteopenia
- Trial name
- NCT00089661
- Testing
- AMG 162 / Denosumab
- Volunteers
- 252 people
- Sponsor
- Amgen
Breast Cancer
Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer
This is a two arm, double-blind randomized study looking at the effect of zoledronate, a bisphosphonate, on the bone mineral density (BMD) of postmenopausal women with breast cancer.
- Trial name
- NCT00213980
- Testing
- Zoledronate
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Wisconsin, Madison
Breast Cancer, Breast - Female
An Investigation Into Dielectric Testing for the Evaluation and Characterisation of Breast Tissue Using a Novel Time-Domain Bioimpedance Tool
Capacitance measures a material's ability to store the movement of electrical energy in the electric field. Different of the human body are known to have different capacitance values.
- Trial name
- DiTECT (NCT07782814)
- Testing
- TD-BIS scanner
- Where
- United Kingdom
- Volunteers
- 220 people
- Sponsor
- Zedsen Limited
Breast Cancer
Radiologic Evaluation and Breast Density (READ)
The purpose of this study is to determine whether cessation of hormone replacement therapy for one or two months before a screening mammogram will improve its performance by decreasing breast density.
- Trial name
- NCT00117663
- Testing
- temporary discontinuation of hormone therapy for 1 month, temporary discontinuation of hormone therapy for 2 months
- Where
- United States
- Volunteers
- 1,704 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Breast Neoplasms
Delphinus SoftVue Prospective Case Collection - ARM 1
The SoftVue™ is a whole breast ultrasound system with an automated scanning curvilinear ring-array transducer that employs UST. It is currently cleared under FDA 510(k) K123209 and K142517 for use as both a B-mode ultrasonic…
- Trial name
- SV PCC ARM1 (NCT03257839)
- Testing
- Routine Full-Field Digital Mammography, Routine Digital Breast Tomosynthesis, Automated Whole Breast Ultrasound
- Where
- 10 sites in United States
- Volunteers
- 7,409 people, healthy volunteers welcome
- Sponsor
- Delphinus Medical Technologies, Inc.
Hormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women
A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer
Estrogen is known to be a regulator of bone and lipid metabolism. Letrozole is a potent inhibitor of estrogen synthesis. This study evaluated the effects of letrozole and tamoxifen on bone and lipid metabolism in postmenopausal…
- Trial name
- NCT00171704
- Testing
- Letrozole, Tamoxifen
- Where
- 13 sites in Denmark, United Kingdom
- Volunteers
- 263 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
A Study, Comparing a Dose-Titration Regimen of Fulvestrant With the Approved Dosing Regimen in Postmenopausal Patients With Hormone-Responsive Advanced Breast Cancer (ABC)
In post-menopausal metastatic hormone-responsive breast cancer women. This study is a two arm randomized trial to evaluate the effectiveness of dose-titration regimen of fulvestrant compared with the approved dosing regimen.
- Trial name
- FIDeS (NCT00927511)
- Testing
- Fulvestrant
- Where
- Italy
- Volunteers
- 104 people
- Sponsor
- Regina Elena Cancer Institute
Breast Cancer
Effect of 4-Hydroxytamoxifen Gel on Breast Density, Salivary Sex Steroids, and Quality of Life in Premenopausal Women
RATIONALE: High estrogen levels may be associated with dense breast tissue and an increased risk of developing breast cancer. 4-hydroxytamoxifen gel (a substance made when tamoxifen breaks down in the body) may be effective in…
- Trial name
- NCT00084344
- Testing
- 4-hydroxytamoxifen, breast imaging study, radiomammography
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Northwestern University
Osteoporosis
Study Evaluating Changes In Mammographic Breast Density
The objective of the study is to evaluate quantitative changes in mammographic breast density from baseline to 24 months in postmenopausal women receiving daily doses of either BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg…
- Trial name
- NCT00774267
- Testing
- BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg, Raloxifene 60 mg
- Where
- 26 sites in United States, Brazil and 2 more
- Volunteers
- 507 people
- Sponsor
- Pfizer